Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Lowered by Wall Street Zen

Iterum Therapeutics (NASDAQ:ITRM) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Iterum Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.00.

Iterum Therapeutics Trading Up 3.8%

NASDAQ ITRM opened at $0.60 on Friday. Iterum Therapeutics has a 1 year low of $0.57 and a 1 year high of $3.02. The company has a market cap of $29.07 million, a PE ratio of -0.71 and a beta of 3.09. The stock’s 50-day moving average price is $0.69 and its two-hundred day moving average price is $0.84.

Hedge Funds Weigh In On Iterum Therapeutics

A hedge fund recently bought a new stake in Iterum Therapeutics stock. Jane Street Group LLC purchased a new position in Iterum Therapeutics PLC (NASDAQ:ITRM) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 92,943 shares of the company’s stock, valued at approximately $92,000. Jane Street Group LLC owned about 0.21% of Iterum Therapeutics at the end of the most recent quarter. Institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.